Deciphera Pharmaceuticals LLC Alpha and Beta Analysis
| DCPHDelisted Stock | USD 13.32 0.36 2.63% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Deciphera Pharmaceuticals LLC. It also helps investors analyze the systematic and unsystematic risks associated with investing in Deciphera Pharmaceuticals over a specified time horizon. Remember, high Deciphera Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Deciphera Pharmaceuticals' market risk premium analysis include:
Beta 0.0 | Alpha 0.0 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Deciphera |
Deciphera Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Deciphera Pharmaceuticals market risk premium is the additional return an investor will receive from holding Deciphera Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Deciphera Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Deciphera Pharmaceuticals' performance over market.| α | 0.00 | β | 0.00 |
Deciphera Pharmaceuticals Fundamentals Vs Peers
Comparing Deciphera Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Deciphera Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Deciphera Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Deciphera Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Deciphera Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Deciphera Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Deciphera Pharmaceuticals to competition |
| Fundamentals | Deciphera Pharmaceuticals | Peer Average |
| Return On Equity | -0.5 | -0.31 |
| Return On Asset | -0.27 | -0.14 |
| Profit Margin | (1.09) % | (1.27) % |
| Operating Margin | (1.09) % | (5.51) % |
| Current Valuation | 1.97 B | 16.62 B |
| Shares Outstanding | 86.48 M | 571.82 M |
| Shares Owned By Insiders | 28.48 % | 10.09 % |
Deciphera Pharmaceuticals Opportunities
Deciphera Pharmaceuticals Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
About Deciphera Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Deciphera or other delisted stocks. Alpha measures the amount that position in Deciphera Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Deciphera Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Deciphera Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Deciphera Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Deciphera Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Deciphera Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Deciphera Pharmaceuticals' management manipulating its earnings.
| 6th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Deciphera Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Deciphera Stock
If you are still planning to invest in Deciphera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Deciphera Pharmaceuticals' history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |